cinclus pharma header news



News and press releases

Welcome to our media section. Check out the latest news and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information. 

Media gallery

Cinclus Pharma Charlotte

Charlotte Stjerngren

Press and IR

E-mail: Send e-mail

E-mail: Send e-mail

Phone: +46 708 768 787

Latest pressreleases

See allSubscribe

Latest News

Cinclus News Research 65255460

Cinclus Pharma announces positive FDA interaction

Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted…

Cinclus News Pr Okt 01

Cinclus Pharma's phase II eGERD study in two presentations at UEG

Two abstracts from Cinclus Pharma's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European…

Cinclus Lennart Hansson 02

Lennart Hansson, visionary and experienced Chairman of the Board

Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various biotech and pharmaceutical companies. He has also worked at AstraZeneca on gastrointestinal diseases and has served on more…

Cinclus News Christer Finansieringsevent 02

Cinclus Pharma at ABGSC - Life Science Summit 2023

Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the ABGSC Life Science Summit on May 30-31, 2023.